BR9806174A - Péletes tendo um núcleo revestido com um antifúngico e um polìmero - Google Patents

Péletes tendo um núcleo revestido com um antifúngico e um polìmero

Info

Publication number
BR9806174A
BR9806174A BR9806174-7A BR9806174A BR9806174A BR 9806174 A BR9806174 A BR 9806174A BR 9806174 A BR9806174 A BR 9806174A BR 9806174 A BR9806174 A BR 9806174A
Authority
BR
Brazil
Prior art keywords
pellets
antifungal
polymer
core coated
pets
Prior art date
Application number
BR9806174-7A
Other languages
English (en)
Inventor
Roger Petrus Gerebe Vandecruys
Valentin Florent Victor Conde
Paul Marie Victor Gilis
Jozef Peeters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BR9806174A publication Critical patent/BR9806174A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Patente de Invenção:<B>"PéLETES TENDO UM NúCLEO REVESTIDO COM UM ANTIFúNGICO E UM POLìMERO"<D>. A presente invenção é concernida com péletes compreendendo esferas de açúcar de 250 a 355 <109>m (malha de 45 a 60), uma película de revestimento de um polímero solúvel em água e um agente antifúngico, e uma camada de revestimento de selo; formas de dosagem farmacêuticas compreendendo os referidos péletes e um método de preparar os referidos péletes.
BR9806174-7A 1997-03-26 1998-03-18 Péletes tendo um núcleo revestido com um antifúngico e um polìmero BR9806174A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97200914 1997-03-26
PCT/EP1998/001773 WO1998042318A1 (en) 1997-03-26 1998-03-18 Pellets having a core coated with an antifungal and a polymer

Publications (1)

Publication Number Publication Date
BR9806174A true BR9806174A (pt) 1999-10-19

Family

ID=8228147

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9806174-7A BR9806174A (pt) 1997-03-26 1998-03-18 Péletes tendo um núcleo revestido com um antifúngico e um polìmero

Country Status (31)

Country Link
EP (1) EP0969821B1 (pt)
JP (1) JP3608800B2 (pt)
KR (1) KR100520936B1 (pt)
CN (1) CN1206984C (pt)
AP (1) AP1227A (pt)
AT (1) ATE241969T1 (pt)
AU (1) AU734248B2 (pt)
BG (1) BG64434B1 (pt)
BR (1) BR9806174A (pt)
CA (1) CA2269501C (pt)
CY (1) CY2384B1 (pt)
CZ (1) CZ295502B6 (pt)
DE (1) DE69815316T2 (pt)
DK (1) DK0969821T3 (pt)
EE (1) EE03904B1 (pt)
ES (1) ES2201485T3 (pt)
HK (1) HK1022840A1 (pt)
HU (1) HU224217B1 (pt)
ID (1) ID21477A (pt)
IL (1) IL129575A (pt)
NO (1) NO325102B1 (pt)
NZ (1) NZ335364A (pt)
OA (1) OA11162A (pt)
PL (1) PL190566B1 (pt)
PT (1) PT969821E (pt)
RU (1) RU2218153C2 (pt)
SI (1) SI0969821T1 (pt)
SK (1) SK284813B6 (pt)
TR (1) TR199900990T2 (pt)
UA (1) UA60318C2 (pt)
WO (1) WO1998042318A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR200002217T2 (tr) * 1998-07-17 2001-02-21 Janssen Pharmaceutica N.V. Bir mantar ilacı ve bir polimer ile kaplanmış bir çekirdeğe sahip taneler.
ES2157731B1 (es) 1998-07-21 2002-05-01 Liconsa Liberacion Controlada Preparacion farmaceutica oral de un compuesto de actividad antifungica y procedimiento para su preparacion.
DE60023465T2 (de) 1999-03-24 2006-07-20 R.P. Scherer Technologies, Inc., Las Vegas Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
KR100432949B1 (ko) * 2000-06-13 2004-05-31 코오롱제약주식회사 생체이용율이 향상된 이트라코나졸의 분립체 조성물과이를 이용한 이트라코나졸 제제 및 그 제조방법
US6663897B2 (en) * 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
EE05385B1 (et) 2001-02-14 2011-02-15 Tibotec�Pharmaceuticals�Ltd. LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
CN100491360C (zh) 2001-04-09 2009-05-27 泰博特克药品有限公司 广谱2-(取代的-氨基)-苯并唑磺酰胺hiv蛋白酶抑制剂
AU2002310818B2 (en) 2001-05-11 2007-12-13 Tibotec Pharmaceuticals Ltd. Broadspectrum 2-amino-benzoxazole sulfonamide HIV protease inhibitors
WO2002100407A1 (en) * 2001-06-12 2002-12-19 Smartrix Technologies Inc. Itraconazole granulations: pharmaceutical formulations for oral administration and method of preparing same
US8071133B2 (en) 2001-08-20 2011-12-06 Stiefel Laboratories, Inc. Oral dosage forms of water insoluble drugs and methods of making the same
BR0215260A (pt) 2001-12-21 2004-12-07 Tibotec Pharm Ltd Inibidores de hiv protease de sulfonamida contendo fenila substituìda heterocìclica de amplo espectro
MY142238A (en) 2002-03-12 2010-11-15 Tibotec Pharm Ltd Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
IL165043A0 (en) 2002-05-17 2005-12-18 Tibotec Pharm Ltd broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
CA2493940C (en) 2002-08-14 2011-11-22 Tibotec Pharmaceuticals Ltd. Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
KR100557680B1 (ko) * 2002-11-23 2006-03-07 한국유나이티드제약 주식회사 이트라코나졸의 용해도 개선을 위한 펠렛제제 및 그제조방법
DE60312636T3 (de) * 2003-01-14 2014-12-24 Acino Pharma Ag Bioaequivalente Zusammensetzung in der Form einer festen Dispersion enthaltend Itraconazol und ein hydrophiles Polymer
ES2283724T5 (es) * 2003-01-14 2013-04-09 Acino Pharma Ag Composición de itraconazol dispersada en un polímero hidrófilo con biodisponibilidad potenciada
EP1651192A1 (en) * 2003-08-06 2006-05-03 Nirmal Mulye Pharmaceutical composition containing water soluble drug
CN1849117B (zh) 2003-09-11 2010-05-26 泰博特克药品有限公司 Hiv病毒的侵入抑制剂
EP1568369A1 (en) 2004-02-23 2005-08-31 Boehringer Ingelheim Vetmedica Gmbh Use of meloxicam for the treatment of respiratory diseases in pigs
AR048650A1 (es) 2004-05-04 2006-05-10 Tibotec Pharm Ltd Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
US7378441B2 (en) 2004-05-07 2008-05-27 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
CN1953982B (zh) 2004-05-17 2011-07-06 泰博特克药品有限公司 4-取代-1,5-二氢-吡啶并[3,2-b]吲哚-2-酮
AP2006003791A0 (en) 2004-05-17 2006-10-31 Tibotec Pharm Ltd 1-Heterocyclyl-1,5-dihydro-pyridoÄ3,2-BÜindol-2-ones
BRPI0511173A (pt) 2004-05-17 2007-12-04 Tibotec Pharm Ltd 1-fenil-1,5-diidro-pirido-(3,2b)indol-2-onas substituìdas nas posições 6,7,8,9, de utilidade como agentes farmacêuticos antiinfecciosos
US7994187B2 (en) 2006-04-03 2011-08-09 Tibotec Pharmaceuticals Ltd. HIV inhibiting 3,4-dihydro-imidazo[4,5-B]pyridin-5-ones
CA2661172A1 (en) * 2006-09-04 2008-05-29 Panacea Biotec Limited Programmable buoyant delivery technology
KR100809903B1 (ko) * 2006-09-05 2008-03-06 주식회사유한양행 안정화된 클로피도그렐-함유 입자, 그의 제조방법, 및 이를포함하는 약학 조성물
CN101283984B (zh) * 2007-04-12 2010-05-26 永胜药品工业股份有限公司 高生物使用率的经杀真菌剂和聚合物涂覆的核心微粒状物
JP2008280254A (ja) * 2007-05-08 2008-11-20 Everest Pharm Industrial Co Ltd 生体に使用される比率が高い、殺菌剤と重合物を塗粧してる核心微粒状物
US8313527B2 (en) 2007-11-05 2012-11-20 Allergan, Inc. Soft prosthesis shell texturing method
JP5745855B2 (ja) 2007-11-28 2015-07-08 セコイア、ファーマシューティカルズ、インコーポレイテッドＳｅｑｕｏｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． シトクロムｐ４５０ ２ｄ６を阻害するための組成物および方法
US8906647B2 (en) 2008-02-21 2014-12-09 Sequoia Pharmaceuticals, Inc. Diamide inhibitors of cytochrome P450
US9050184B2 (en) 2008-08-13 2015-06-09 Allergan, Inc. Dual plane breast implant
US8877822B2 (en) 2010-09-28 2014-11-04 Allergan, Inc. Porogen compositions, methods of making and uses
US9138309B2 (en) 2010-02-05 2015-09-22 Allergan, Inc. Porous materials, methods of making and uses
US9205577B2 (en) 2010-02-05 2015-12-08 Allergan, Inc. Porogen compositions, methods of making and uses
SG174658A1 (en) 2010-04-01 2011-10-28 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
US11202853B2 (en) 2010-05-11 2021-12-21 Allergan, Inc. Porogen compositions, methods of making and uses
CN102971018B (zh) * 2010-05-11 2016-02-03 阿勒根公司 致孔剂组合物、制备方法及用途
US8679279B2 (en) 2010-11-16 2014-03-25 Allergan, Inc. Methods for creating foam-like texture
CN102100678B (zh) * 2011-02-18 2012-10-17 天津力生制药股份有限公司 伊曲康唑硫酸盐微丸及其制备方法
AU2013359158B2 (en) 2012-12-13 2018-08-02 Allergan, Inc. Device and method for making a variable surface breast implant
US10092392B2 (en) 2014-05-16 2018-10-09 Allergan, Inc. Textured breast implant and methods of making same
JP6841834B2 (ja) 2016-01-20 2021-03-10 テラヴィダ, インコーポレイテッドTheraVida, Inc. 多汗症の処置のための方法および組成物
CA3097176A1 (en) * 2018-04-16 2019-10-24 Bristol-Myers Squibb Company Apixaban formulations
CN114767636B (zh) * 2022-04-11 2023-11-07 苏州中化药品工业有限公司 伊曲康唑微丸、制备方法及伊曲康唑微丸胶囊

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
GB8506792D0 (en) * 1985-03-15 1985-04-17 Janssen Pharmaceutica Nv Derivatives of y-cyclodextrin
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
WO1998000116A1 (en) * 1996-06-28 1998-01-08 Schering Corporation Oral composition comprising a triazole antifungal compound

Also Published As

Publication number Publication date
CA2269501C (en) 2005-11-08
RU2218153C2 (ru) 2003-12-10
PL335542A1 (en) 2000-04-25
DE69815316T2 (de) 2004-04-29
ES2201485T3 (es) 2004-03-16
NZ335364A (en) 2000-08-25
EP0969821A1 (en) 2000-01-12
PL190566B1 (pl) 2005-12-30
ID21477A (id) 1999-06-17
HK1022840A1 (en) 2000-08-25
CZ295502B6 (cs) 2005-08-17
EP0969821B1 (en) 2003-06-04
SI0969821T1 (en) 2003-10-31
CY2384B1 (en) 2004-06-04
TR199900990T2 (xx) 1999-10-21
DK0969821T3 (da) 2003-09-15
EE9900453A (et) 2000-04-17
ATE241969T1 (de) 2003-06-15
AP1227A (en) 2003-11-24
NO325102B1 (no) 2008-02-04
BG64434B1 (en) 2005-02-28
NO992114D0 (no) 1999-04-30
WO1998042318A1 (en) 1998-10-01
SK54499A3 (en) 2000-01-18
NO992114L (no) 1999-08-26
IL129575A0 (en) 2000-02-29
HU224217B1 (hu) 2005-06-28
CZ139899A3 (cs) 1999-10-13
AP9901516A0 (en) 1999-06-30
CA2269501A1 (en) 1998-10-01
KR20000052971A (ko) 2000-08-25
KR100520936B1 (ko) 2005-10-17
OA11162A (en) 2003-04-16
JP3608800B2 (ja) 2005-01-12
CN1244796A (zh) 2000-02-16
DE69815316D1 (de) 2003-07-10
PT969821E (pt) 2003-10-31
IL129575A (en) 2004-06-20
SK284813B6 (sk) 2005-12-01
HUP0002056A2 (hu) 2000-12-28
JP2001520663A (ja) 2001-10-30
AU734248B2 (en) 2001-06-07
HUP0002056A3 (en) 2001-01-29
EE03904B1 (et) 2002-12-16
CN1206984C (zh) 2005-06-22
AU7210798A (en) 1998-10-20
UA60318C2 (uk) 2003-10-15
BG103356A (en) 2000-03-31

Similar Documents

Publication Publication Date Title
BR9806174A (pt) Péletes tendo um núcleo revestido com um antifúngico e um polìmero
BR9906712A (pt) Péletes que apresentam um núcleo revestido com um antifúngico e um polìmero
KR920703030A (ko) 방출 지연 조성물
KR930003905A (ko) 약학적 결합 제제
BR9806238A (pt) Partìculas revestidas: processos de obtenção e uso
DE69915346D1 (de) Umwandlung von flüssigkeitsgefüllten gelatinkapseln in systeme mit gesteuerter wirkstoffabgabe durch mehrfache beschichtungen
CA2304110A1 (en) Theophylline sustained release tablet
DE69832092D1 (de) VERBESSERTE HMG CoA REDUKTASE-INHIBITOR FORMULIERUNG MIT VERLÄNGERTER FREISETZUNG
BR9904039A (pt) Preparação de partìculas farmaceuticamente ativas
CA2338780A1 (en) Preparation capable of releasing medicinal substance at targeted site in intestine
DE60036874D1 (de) Pellet formulierung mit gesteuerter freisetzung
BR9807368A (pt) Comprimidos de oxacarvazepina revestidos com pelìcula
FI853934L (fi) Doseringssystem som bestaor av flera enheter och har en belaeggning som tillaoter diffusion.
ATE186211T1 (de) Verfahren zu herstellung einer manteltablette mit spitzem kern
DE69626579D1 (de) Wasserabweisende Zusammensetzung, Fluorkohlenstoffpolymerbeschichtungszusammensetzung und Beschichtungsfilm
GR3001238T3 (en) Process for the preparation of an administration and dosage for drugs, reagents or other active substances
PT630646E (pt) Formulacoes de libertacao controlada revestidas com dispersoes aquosas de etilcelulose
ES2191984T3 (es) Microparticulas y su utilizacion terapeutica o para diagnosticos.
ATE244001T1 (de) Verabreichungssystem mit gesteuerter freisetzung einer arzneistoffsuspension
KR890007720A (ko) 조절 방출성 용량 형태
ATE251899T1 (de) Pharmazeutische dosierungsform zur freisetzung im colon
WO2002024174A3 (en) Sustained release composition containing clarithromycin
BR9104402A (pt) Polimero de emulsao diluivel na agua,processo para a preparacao de um polimero de emulsao diluivel na agua,composicao de revestimento aquosa e emprego do polimero
NO973950L (no) Peroral sammensetning for kontrollert frigjöring i nedre gastrointestinaltrakt
BR0202491A (pt) Forma de dosagem de núcleo macio, de revestimento frágil

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 9/50, A61K 9/48, A61K 31/496, A61K 47/10, A61K 47/68, A61P 31/10

Ipc: A61K 9/50 (2008.04), A61K 9/48 (2008.04), A61K 31/

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO COM BASE NOS ARTIGOS 8O, 11, 13 E 25 DA LEI 9.279 DE 14 DE MAIO DE 1996 ( LPI )

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.